Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Approval of Aducanumab for Alzheimer Disease-The FDA's Perspective.

× No keyword cloud information.

41 in total

Review 1. Can we learn lessons from the FDA's approval of aducanumab?

Authors: Kathy Y Liu; Robert Howard
Journal: Nat Rev Neurol Date: 2021-09-17 Impact factor: 42.937

Review 2. Microglia Phenotypes in Aging and Neurodegenerative Diseases.

Authors: Menbere Y Wendimu; Shelley B Hooks
Journal: Cells Date: 2022-06-30 Impact factor: 7.666

3. Aducanumab: Appropriate Use Recommendations Update.

Authors: J Cummings; G D Rabinovici; A Atri; P Aisen; L G Apostolova; S Hendrix; M Sabbagh; D Selkoe; M Weiner; S Salloway
Journal: J Prev Alzheimers Dis Date: 2022

4. Predictors of response to acetylcholinesterase inhibitors in dementia: A systematic review.

Authors: Federico Emanuele Pozzi; Elisa Conti; Ildebrando Appollonio; Carlo Ferrarese; Lucio Tremolizzo
Journal: Front Neurosci Date: 2022-09-20 Impact factor: 5.152

5. Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease: Two Phase 3 Randomized Placebo-Controlled Trials.

Authors: Susanne Ostrowitzki; Tobias Bittner; Kaycee M Sink; Howard Mackey; Christina Rabe; Lawrence S Honig; Emanuele Cassetta; Michael Woodward; Mercè Boada; Christopher H van Dyck; Timo Grimmer; Dennis J Selkoe; Andres Schneider; Kathleen Blondeau; Nan Hu; Angelica Quartino; David Clayton; Michael Dolton; Yifan Dang; Beth Ostaszewski; Sandra M Sanabria-Bohórquez; Michael Rabbia; Balazs Toth; Udo Eichenlaub; Jillian Smith; Lee A Honigberg; Rachelle S Doody
Journal: JAMA Neurol Date: 2022-09-19 Impact factor: 29.907

Review 6. Potential disease-modifying therapies for Huntington's disease: lessons learned and future opportunities.

Authors: Sarah J Tabrizi; Carlos Estevez-Fraga; Willeke M C van Roon-Mom; Michael D Flower; Rachael I Scahill; Edward J Wild; Ignacio Muñoz-Sanjuan; Cristina Sampaio; Anne E Rosser; Blair R Leavitt
Journal: Lancet Neurol Date: 2022-07 Impact factor: 59.935

Review 7. Advanced molecular therapies for neurological diseases: focus on stroke, alzheimer's disease, and parkinson's disease.

Authors: Madhumitha Katta; Blessy Aksa Mathew; Pragya Chaturvedi; Abhilash Ludhiadch; Anjana Munshi
Journal: Neurol Sci Date: 2022-09-06 Impact factor: 3.830

Approval of Aducanumab for Alzheimer Disease-The FDA's Perspective.